DERMATOLOGIC TOXICITY and INFUSION REACTIONS
See full prescribing information for complete boxed warning.
- TRADE NAME: Vectibix (Amgen)
- INDICATIONS: Metastatic colorectal carcinoma progression
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Monoclonal antibody
- HALF-LIFE: ~7.5 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Epidermal growth factor receptor (EGFR) inhibitor / antagonist
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of panitumumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/01/2024
